, Tracking Stock Market Picks
Enter Symbol:
Alexion Pharmaceuticals, Inc. (ALXN) [hlAlert]

up 1,848.74 %

Alexion Pharmaceuticals, Inc. (ALXN) rated Buy with price target $84 by Brean Murray

Posted on: Friday,  Sep 23, 2011  4:25 PM ET by Brean Murray

Brean Murray rated Buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) on 09/23/2011. Previously Brean Murray rated Buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) on
03/19/2009., when the stock price was $9.23. Since then, Alexion Pharmaceuticals, Inc. has gained 1848.74% as of 12/11/2015's recent price of $179.82.
If you would have followed the previous Brean Murray's recommendation on ALXN, you would have gained 1848.74% of your investment in 2458 days.

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/23/2011 4:25 PM Buy
67.41 84.00
as of 12/30/2011
1 Week up  3.50 %
1 Month up  4.13 %
3 Months up  11.61 %
1 YTD up  77.52 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/21/2011 1:25 PM Buy
57.14 60.00
4/21/2011 1:25 PM Buy
24.65 28.50
1/26/2011 9:25 AM Buy
21.42 23.25
11/22/2010 8:25 AM Buy
18.68 20.75
9/29/2010 8:25 AM Buy
16.21 18.75
4/23/2010 8:25 AM Buy
13.86 16.50
7/23/2009 8:55 PM Buy
10.41 11.50
3/19/2009 9:25 AM Buy
9.23 10.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy